The Technical Analyst
Deciphera Pharmaceuticals [DCPH]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Deciphera Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.62% $14.67
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 185.34 mill |
| EPS: | -2.29 |
| P/E: | -6.41 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 80.80 mill |
| Avg Daily Volume: | 0.515 mill |
| RATING 2024-04-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.41 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.13x |
| Company: PE -6.41 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 14.01 - 15.33 ( +/- 4.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-15 | Sherman Matthew L | Buy | 17 275 | Common Stock |
| 2024-02-16 | Sherman Matthew L | Sell | 2 615 | Common Stock |
| 2024-02-15 | Sherman Matthew L | Buy | 69 100 | Stock Option (Right to Buy) |
| 2024-02-15 | Kelly Thomas Patrick | Buy | 17 275 | Common Stock |
| 2024-02-16 | Kelly Thomas Patrick | Sell | 3 010 | Common Stock |
| INSIDER POWER |
|---|
| 31.78 |
| Last 99 transactions |
| Buy: 6 983 334 | Sell: 3 513 431 |
Forecast:
16:00 - $14.67
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $14.67
Forecast 2: 16:00 - $14.67
Forecast 3: 16:00 - $14.67
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.67 (0.62% ) |
| Volume | 0.414 mill |
| Avg. Vol. | 0.515 mill |
| % of Avg. Vol | 80.42 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DCPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $14.14 | N/A | Active |
|---|
DCPH
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Latest Press Releases
2024-04-18 08:45:00 - Press Release
Shareholder Alert: Purcell & Lefkowitz Llp Announces Shareholder Investigation Of Deciphera Pharmaceuticals, Inc. (nasdaq: Dcph)
New york , april 18, 2024 /prnewswire/ -- purcell & lefkowitz llp announces that it is investigating deciphera pharmaceuticals, inc. (nasdaq: dcph) on behalf of the company's shareholders. the investigation seeks to determine whether deciphera pharmaceuticals, inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
2024-04-09 07:00:00 - Press Release
Deciphera Pharmaceuticals To Present At The Stifel 2024 Virtual Targeted Oncology Forum
Waltham, mass.--(business wire)--deciphera pharmaceuticals, inc. (nasdaq: dcph), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the stifel 2024 virtual targeted oncology forum on tuesday, april 16, 2024 at 11:30 am et. a live webcast of the fireside chat will be available on the “events and presentatio.
2024-02-27 07:00:00 - Press Release
Deciphera Pharmaceuticals To Participate In Upcoming Investor Conferences
Waltham, mass.--(business wire)--deciphera pharmaceuticals, inc. (nasdaq: dcph), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: td cowen 44th annual health care conference on tuesday, march 5, 2024 at 1:30 pm et in boston, ma leerink partners global biopharma conferen.
2024-02-06 07:00:00 - Press Release
Deciphera Pharmaceuticals Announces Fourth Quarter And Full Year 2023 Financial Results
Waltham, mass.--(business wire)--deciphera pharmaceuticals, inc. (nasdaq: dcph), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended december 31, 2023 and provided a corporate update. “we are proud of the significant progress we made across our company throughout 2023, particularly in our late-stage programs as we continue on.
2024-02-01 16:50:00 - Press Release
Deciphera Pharmaceuticals To Announce Fourth Quarter And Full Year 2023 Financial Results And Host Conference Call And Webcast On February 6, 2024
Waltham, mass.--(business wire)--deciphera pharmaceuticals, inc. (nasdaq: dcph), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on tuesday, february 6, 2024. in connection with the earnings release, deciphera's management team will host a live conference call and webcast at 8:00 am et on tuesday, febr.
Latest News
2024-03-07 12:36:59 - Zacks Investment Research
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?
2024-02-28 10:56:04 - Zacks Investment Research
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet
The consensus price target hints at a 48.5% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-02-12 10:56:08 - Zacks Investment Research
Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 59.6% in Deciphera Pharmaceuticals, Inc. (DCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-07 09:31:28 - Zacks Investment Research
Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat
Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.
2024-02-01 16:50:00 - Business Wire
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Tuesday, Febr.
2024-01-09 04:37:11 - Seeking Alpha
Deciphera: Upside Potential For The Patient Investor
Deciphera Pharmaceuticals has seen a 50% upside with successful phase 3 trial results. DCPH has achieved positive data in a subpopulation of patients with KIT exon 11 primary mutation. The company's pivotal phase 3 study of vimseltinib in TGCT has met primary and secondary endpoints, with a high objective response rate.
2024-01-07 23:48:01 - Seeking Alpha
Deciphera Pharmaceuticals: Moving The Needle Where It Counts
Deciphera Pharmaceuticals continues to make progress with its flagship drug ripretinib, with positive phase 3 results and ongoing trials. They are also working on commercializing the CSF1R inhibitor vimseltinib, with promising response rates in phase 1/2 and phase 3 trials. Financially, DCPH has a strong cash position and increasing revenues, but high expenses and the need for profitability remain challenges.
2024-01-02 07:00:00 - Business Wire
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 4:30 PM PT / 7:30 PM ET. A live webcast of the event will be available on the “Events and Pres.
2023-10-31 09:01:55 - Zacks Investment Research
Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat
Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.
2023-10-30 09:46:23 - Zacks Investment Research
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.55 per share a year ago.